| Literature DB >> 24822189 |
Yun Ji Hong1, Mi Suk Lim2, Sang Mee Hwang1, Taek Soo Kim1, Kyoung Un Park1, Junghan Song1, Eui Chong Kim3.
Abstract
Herpes simplex viruses types 1 and 2 (HSV-1 and HSV-2), and varicella-zoster virus (VZV) are common agents resulting in various forms of clinical manifestation from skin vesicle to disseminated viral infection. The aim of the present study was to develop a real-time PCR and melting curve analysis which detect and differentiate HSV-1, HSV-2, and VZV, to compare with PCR-RFLP using clinical specimens, and to introduce the 4-year experience in the clinical laboratory. Three pairs of primers for HSV-1, HSV-2, and VZV were designed. Primers for human endogenous retrovirus-3 (HERV-3), an internal control, were adopted. A hundred selected specimens and many clinical specimens were tested for methods comparison and assay validation. Increased sensitivity and specificity were obtained from real-time PCR. In review of results of clinical specimens submitted to clinical laboratory, a total of 46 of 3,513 specimens were positive in cerebrospinal fluids, blood, skin vesicles, genital swabs, aqueous humor, and ear discharge. Thus, this method could be a rapid and accurate alternative to virus culture and other molecular tests for detection and typing of HSV-1, HSV-2, and VZV.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24822189 PMCID: PMC4009197 DOI: 10.1155/2014/261947
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Primer sequences used and product sizes of each target genes for HSV-1, HSV-2, VZV, and HERV-3.
| Virus | Gene target | Primer sequences (5′→3′) | Amplicon (bp) | Reference |
|---|---|---|---|---|
| HSV-1 |
| Forward primer: GGTCTCTTTTGTGTGGTGC | 84 | This study |
| Reverse primer: GCCCACTATGACGACAAAC | This study | |||
|
| ||||
| HSV-2 |
| Forward primer: TACGCTCTCGTAAATGCTTC | 120 | This study |
| Reverse primer: GCCCACCTCTACCCACAA | This study | |||
|
| ||||
| VZV |
| Forward primer: GCCCATGAATCACCCTC | 79 | This study |
| Reverse primer: ACTCGGTACGCCATTTAG | This study | |||
|
| ||||
| HERV-3 |
| Forward primer: CATGGGAAGCAAGGGAACTAATG | 135 | Yuan et al., 2001 [ |
| Reverse primer: CCCAGCGAGCAATACAGAATTT | Yuan et al., 2001 [ | |||
HSV: herpes simplex virus; VZV: varicella-zoster virus; HERV-3: human endogenous retrovirus; gpD: glycoprotein D; gpG: glycoprotein G; ORF4: open reading frame 4.
Figure 1Differentiation of HSV-1, HSV-2, and VZV by multiplex real-time PCR-melting curve analysis. Melting peaks of HSV-1, HSV-2, and VZV positive samples by melting curve analysis. The HSV-1 amplicon has a melting temperature around 86.89°C, HSV-2 around 89.08°C, and VZV around 78.58°C, and internal control has a melting temperature around 82.41°C. HSV: herpes simplex virus; VZV: varicella-zoster virus; HERV-3: human endogenous retrovirus; I.C.: internal control.
Comparison of real-time PCR, PCR-RFLP, and virus culture for the detection of HSV-1, HSV-2, and VZV during the validation phase.
| Virus | Real-time PCR | PCR-RFLP | Virus culture | |||
|---|---|---|---|---|---|---|
| Positive | Negative | Positive | Negative | Positive | Negative | |
| HSV-1 | 9 | 91 | 8 | 92 | 4 | 96 |
| HSV-2 | 6 | 94 | 6 | 94 | 4 | 96 |
| VZV | 19 | 81 | 13 | 87 | 0 | 100 |
HSV: herpes simplex virus; VZV: varicella-zoster virus.
Summary of specimen types and numbers positive for HSV-1, HSV-2, and VZV.
| Specimen type | Number tested | Number positive | |||
|---|---|---|---|---|---|
| HSV-1 and HSV-2 | VZV | HSV-1 | HSV-2 | VZV | |
| CSF | 2,495 | 755 | 3 | 4 | 23 |
| Blood | |||||
| Serum | 62 | 68 | 0 | 0 | 1 |
| Plasma | 15 | 16 | 1 | 0 | 1 |
| Skin vesicle | 16 | 13 | 1 | 3 | 2 |
| Genital swab | 21 | 0 | 0 | 3 | 0 |
| Oral swab | 4 | 2 | 0 | 0 | 0 |
| Eye | |||||
| Corneal scraping | 11 | 0 | 0 | 0 | 0 |
| Vitreous fluid | 8 | 8 | 0 | 0 | 0 |
| Aqueous humor | 3 | 5 | 0 | 0 | 2 |
| Amniotic fluid | 5 | 1 | 0 | 0 | 0 |
| Urine | 1 | 0 | 0 | 0 | 0 |
| BAL | 0 | 2 | 0 | 0 | 0 |
| Ear discharge | 0 | 1 | 0 | 0 | 1 |
| Tissue (skin) | 1 | 0 | 0 | 0 | 0 |
|
| |||||
| Total | 2,642 | 871 | 5 | 10 | 30 |
HSV: herpes simplex virus; VZV: varicella-zoster virus; CSF: cerebrospinal fluid; BAL: bronchoalveolar lavage.
Clinical and laboratory findings of the patients positive for the presence of HSV or VZV DNA in CSF by PCR.
| Virus detected | Number of positive samples | Age at diagnosis (number of patients) | Clinical diagnosis | Number of immunocompromised patients*/number of immunocompetent patients |
|---|---|---|---|---|
| HSV-1 | 3 | 31–50 (1) | Encephalitis (1) | 0/1 |
| >50 (2) | Encephalitis (2) | 1/1 | ||
|
| ||||
| HSV-2 | 4 | 31–50 (2) | Meningitis (2) | 0/2 |
| >50 (1) | Meningitis (1) | 0/1 | ||
|
| ||||
| VZV | 23 | 10–30 (3) | Meningitis (3) | 0/3 |
| 31–50 (7) | Meningitis (6) | 1/5 | ||
| Myelitis (1) | 0/1 | |||
| >50 (12) | Encephalitis (6) | 4/2 | ||
| Meningitis (4) | 1/3 | |||
| Disseminated viral infection (1) | 1/0 | |||
| Ramsay Hunt syndrome (1) | 0/1 | |||
*Immunocompromised patients include patients who were diagnosed with hematologic malignancy (acute myeloid leukemia, diffuse large B-cell lymphoma, and essential thrombocythemia), solid tumor (breast cancer and cervical cancer), rheumatoid arthritis treated with methotrexate, and diabetes mellitus.
HSV: herpes simplex virus; VZV: varicella-zoster virus.